ValuEngine lowered shares of Zimmer Biomet (NYSE:ZBH) from a buy rating to a hold rating in a research report sent to investors on Friday morning.
ZBH has been the topic of a number of other reports. SunTrust Banks upped their price objective on shares of Zimmer Biomet to $142.00 and gave the company a buy rating in a research note on Monday, January 29th. Canaccord Genuity reaffirmed a hold rating and issued a $125.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, December 19th. Oppenheimer reaffirmed a buy rating on shares of Zimmer Biomet in a research note on Tuesday, December 19th. BMO Capital Markets reaffirmed a buy rating and issued a $144.00 price objective on shares of Zimmer Biomet in a research note on Tuesday, January 30th. Finally, Raymond James Financial started coverage on shares of Zimmer Biomet in a research note on Thursday, March 15th. They issued an outperform rating and a $135.00 price objective on the stock. Two analysts have rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $140.63.
Shares of Zimmer Biomet (NYSE ZBH) opened at $107.44 on Friday. Zimmer Biomet has a 1-year low of $107.32 and a 1-year high of $133.49. The company has a current ratio of 1.50, a quick ratio of 0.81 and a debt-to-equity ratio of 0.76. The firm has a market cap of $21,826.12, a P/E ratio of 11.92, a price-to-earnings-growth ratio of 1.87 and a beta of 1.13.
The business also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. Zimmer Biomet’s payout ratio is presently 10.65%.
In related news, insider Bryan C. Hanson bought 25,077 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were bought at an average price of $119.68 per share, for a total transaction of $3,001,215.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Chad F. Phipps sold 20,826 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $115.95, for a total transaction of $2,414,774.70. The disclosure for this sale can be found here. 1.07% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC raised its holdings in Zimmer Biomet by 18.6% during the third quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock worth $791,000 after buying an additional 1,057 shares during the last quarter. Jana Partners LLC raised its holdings in Zimmer Biomet by 16.6% during the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after buying an additional 662,497 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Zimmer Biomet by 10.0% during the third quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after buying an additional 1,494 shares during the last quarter. WINTON GROUP Ltd acquired a new position in Zimmer Biomet during the third quarter worth $370,000. Finally, Cipher Capital LP acquired a new position in Zimmer Biomet during the third quarter worth $1,225,000. Institutional investors own 86.49% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zimmer Biomet (ZBH) Downgraded to “Hold” at ValuEngine” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3300960/zimmer-biomet-zbh-downgraded-to-hold-at-valuengine.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.